BABahar Artim-Esen

Bahar Artim-Esen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bahar Artim-Esen has a total of 253 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of echocardiographic features and cardiac biomarkers in patients with AA amyloidosis: a retrospective comparative study with patients with al amyloidosis and hypertrophic cardiomyopathy

    by Murat Bektaş, Mehmet Güven Günver, Ömer Uludağ, Ezgi Şahin, Besim Fazıl Ağargün, Gizem Dağcı, Nevzat Koca, Emin Oğuz, Shirkhan Amikishiyev, Burak İnCe, et al.

  • Clinical characteristics of patients with primary antiphospholipid syndrome and “single” antiphospholipid antibody: Retrospective results from the APS ACTION clinical database and repository (“registry”)

    by Silvia Grazietta Foddai, Irene Cecchi, Massimo Radin, Laura Bertolaccini, Danieli de Andrade, Maria Tektonidou, Vittorio Pengo, Chary Lopez-Pedrera, Diana Paredes-Ruiz, Howard Michael Belmont, et al.

    Objective: While triple antiphospholipid antibody (aPL) positivity is associated with a higher risk of thrombosis, the clinical significance of single aPL positivity remains unclear. This study aimed to assess the prevalence, clinical characteristics, and cardiovascular disease (CVD) risk profile of persistently single aPL-positive primary antiphospholipid syndrome (PAPS) patients. Methods: We conducted a retrospective analysis for APS patients from the APS ACTION registry with confirmed persistent single aPL positivity (after testing for lupus anticoagulant [LA], anticardiolipin [aCL] IgG/IgM, or anti-β 2 -glycoprotein I [aβ 2 GPI] IgG/IgM), defined by the Revised Sapporo APS Classification Criteria. Triple aPL-tested single aPL-positive patients with no APS classification were used as a control group. Demographics, clinical characteristics, aPL profiles, and adjusted Global APS Score (aGAPSS) were compared between two groups. Results: Among 233 PAPS patients tested, 84 (36%) had single aPL positivity: 67 (79%) LA positive, eight (10%) aCL IgG or IgM positive, and 9 (11%) aβ 2 GPI IgG or IgM positive. Among 97 aPL-positive patients with no APS classification, 22 (22.7%) had single aPL-positivity: nine LA positive, eight aCL IgG or IgM positive, and 5 aβ 2 GPI IgG or IgM positive. Single LA positivity was significantly more common in PAPS patients, whereas aCL IgM or aβ 2 GPI IgM positivity were significantly more common in those without APS classification. Historical thrombosis recurrence was observed in 26% of single aPL-positive PAPS patients, predominantly among those with LA positivity (86%). Conclusions: In this international cohort of persistently aPL-positive individuals, 36% had single aPL positivity, mostly positive LA test. Although “single” aPL-positivity is traditionally considered as a lower-risk profile, findings highlight the importance of differentiating between single LA-positivity and single aCL/aβ 2 GPI positivity, and the need for individualized risk stratification.

  • Clinical characteristics, organ damage and survival in idiopathic inflammatory myopathies: a long-term retrospective cohort study

    by Ezgi Sahin, Omer Uludag, Yasemin Yalcinkaya, Bahar Artim-Esen, Ahmet Gul, Murat Inanc

    To compare the clinical phenotype, organ damage, and survival of patients with antisynthetase syndrome (ASyS) and other idiopathic inflammatory myopathies (OIIM) in a long-term, single-center retrospective cohort. We retrospectively analyzed patients with idiopathic inflammatory myopathy who fulfilled the Bohan and Peter criteria, the EULAR/ACR classification criteria and had available myositis specific autoantibody results. This cohort comprises patients followed in our autoimmune connective tissue disease clinic between 1991–2024. Demographic, clinical, laboratory, autoantibody, organ damage, and survival data were compared between ASyS and OIIM groups. Myositis Damage Index was used for assessing organ damage at the sixth month of follow-up and the last visit. Of the 122 patients, 35 (28.7%) were classified as ASyS (85.7% female) and 87 as OIIM (59.8% female). Median age at diagnosis was 47 and 46 years, respectively. The mean follow-up duration of the overall cohort was 84.48 ± 77.95 months. Among patients with ASyS, anti-Jo-1 was the most frequent autoantibody detected (88.6%), followed by anti-PL-7 in 8.6% and anti-KS in 2.8%. Mechanic’s hands, arthritis, and interstitial lung disease were more frequent in the ASyS group. Dysphagia was more frequent in the OIIM group (ASyS: 8.6%; OIIM: 37.9%, p = 0.003). Anti-Ro-52 positivity was more common in ASyS than in OIIM (ASyS: 42.9%, OIIM: 21.8%, p = 0.034). C-reactive protein, leukocyte, and neutrophil levels were higher in the ASyS group at baseline. The median Myositis Damage Index score at the sixth month was nominally higher in ASyS than in OIIM (median MDI: 3 vs. 2, p = 0.046). However, MDI scores were comparable between the two groups at the last assessment. In autoantibody-based subgroup analyses, higher early damage scores were observed in ASyS than in anti-TIF1γ-positive patients (median MDI = 3 vs 1.5, p = 0.033). Interstitial lung disease (ILD) was more frequently present in ASyS, whereas malignancy was more frequent among anti-TIF1γ-positive patients. The mortality rate was 14.3% in the ASyS group and 14.9% in the OIIM group. Survival analysis did not reveal a statistically significant difference at the end of the follow-up between ASyS and OIIM groups. In this long-term retrospective cohort, patients with ASyS showed a distinct clinical phenotype compared with OIIM. Sixth-month MDI scores were nominally higher in ASyS and may partly reflect the higher burden of ILD; however, MDI subdomain analyses were not available. No statistically significant difference in survival was detected between groups, although this finding should be interpreted cautiously because of the small number of deaths. Overall, these findings should be considered exploratory and hypothesis-generating and require confirmation in larger multicenter prospective cohorts.

  • Open Access

    CD163: a potential biomarker for lupus nephritis activity

    by Erdem Gürel, Suzan Çinar, Özge Hürdogan, Yasemin Özlük, Gamze Kemeç, Ömer Uludağ, Sibel Varelci, Safak Mirioğlu, Yasemin Yalçinkaya, Ahmet Gül, et al.

    Objectives: CD163 is a macrophage-associated scavenger receptor shed during inflammatory activation, resulting in measurable soluble CD163 in serum (s) and urine (u). Elevated levels have been reported in inflammatory and immune-mediated conditions, including lupus nephritis (LN). This study aimed to investigate the relationship between soluble CD163 levels and intrarenal CD163 expression, evaluating their association with disease activity and treatment response in LN. Methods: Forty-five patients with systemic lupus erythematosus (SLE) were included (20 active LN, 10 inactive LN, 15 active extra-renal SLE), together with 20 matched healthy controls. Serum and urine samples were collected at baseline alongside renal biopsy in active LN; 6-month follow-up samples were available for 12 active LN patients. CD163 was measured by ELISA; urinary CD163 was normalised to spot urine creatinine. Renal biopsies from 20 active LN patients were evaluated for CD163+ macrophage density. Results: uCD163 was higher in active LN (a renal Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) flare (UPCR ≥0.5 g/g) with biopsy-proven active lesions) than in inactive LN and active extra-renal SLE (both p<0.001), discriminating active from inactive LN (area under the curve (AUC) 0.97) and from extra-renal SLE (AUC 0.89). uCD163 correlated with the National Institutes of Health activity and chronicity indices activity index (ρ=0.55, p=0.016) and with glomerular CD163+ macrophage density (the number of CD163+ macrophages per glomerulus quantified by immunohistochemistry; ρ=0.65, p=0.006), but not with chronicity. Glomerular CD163+ macrophage density also correlated with sCD163 (ρ=0.60, p=0.01) and uCD163 (ρ=0.63, p=0.009). After 6-month induction, uCD163 fell from 7.41 to 1.55 ng/mg (p<0.001). Conclusion: uCD163 distinguishes active LN from inactive renal and extra-renal disease and tracks treatment response. The association with intrarenal CD163+ macrophages supports its biological relevance as a non-invasive marker of renal inflammation, complementary to histopathology when repeat biopsy is not feasible. These findings support uCD163 as a candidate non-invasive tool for identifying active LN and monitoring treatment response in SLE, warranting validation in larger prospective cohorts.


  • Association of rheumatoid factor with vasculitic manifestations and distinct clinical patterns in eosinophilic granulomatosis with polyangiitis: a multicenter observational study

    by Burak Ince, Erdem Bektaş, Burcu Yağız, Murat Bektaş, Tuğba Ocak, Cemal Bes, Ediz Dalkılıç, Yasemin Yalçınkaya, Bahar Artım Esen, Sevil Kamalı, et al.

    Eosinophilic granulomatosis with polyangiitis (EGPA) is a heterogeneous disease characterized by overlapping eosinophilic and vasculitic manifestations, and reliable markers reflecting disease phenotype and prognosis remain limited. In this study, we aimed to evaluate the clinical and prognostic significance of rheumatoid factor (RF) positivity in patients with EGPA and to explore phenotypic patterns using cluster analysis. Clinical features, laboratory findings, treatment and outcome data of 50 patients with EGPA from three tertiary referral centers were collected retrospectively and included in the study. RF positivity was defined as titers > 3× the upper limit of normal. RF positivity was observed in 36% of patients and was significantly associated with mononeuritis multiplex (p = 0.03, OR 3.8%95 CI [1.1–12.8]), purpura (p = 0.003, OR 6.8%95 CI [1.8–25.6]), higher C-reactive protein levels at diagnosis (p = 0.014), and shorter relapse-free survival (37.8 ± 8.5 vs. 135 ± 12.8 months, log rank p < 0.001). ANCA status was not associated with relapse risk or overall disease severity. Exploratory cluster analysis identified three phenotypic patterns, including two higher-risk patterns characterized by vasculitic neuropathy and cardiomyopathy, both associated with higher relapse rates and RF positivity, and a third subgroup with milder disease and the highest prevalence of upper respiratory tract involvement. These findings suggest a potential association with RF positivity and a more inflammatory and relapse-prone disease course in EGPA and provide additional clinical information. Integrating RF with key clinical features may improve risk stratification and longitudinal management. Prospective studies in larger cohorts are needed to validate these observations.


  • EVALUATION OF GENETIC TESTING IN ADULT PATIENTS WITH SUSPECTED SYSTEMIC AUTOINFLAMMATORY DISORDERS

    by Shirkhan Amikishiyev, Yıldız Akbal Engin, Tuğba Kalaycı, Lala Soltanova, Yasemin Yalçınkaya, Bahar Artım Esen, Murat İnAnç, Ayla Şahin, Aynur Aday, Sema Ekmekçi, et al.

    Objective: This study aimed to compare the clinical features of patients with suspected systemic autoinflammatory diseases (SAIDs) by genetic status to identify the characteristics of variant-negative patients.Materials and Methods: Clinical findings and results of the targeted next-generation sequencing of “fever panel genes” of patients with suspected SAIDs were retrospectively reviewed using their medical records.Results: Records of 137 patients (79 females, 58 males, mean age 40.8±12.6) referred to our clinic between April 2019 and January 2023 were evaluated. Variants associated with the relevant phenotypes were identified in 105 patients (76.6%), whereas 32 (23.4%) had no pathogenic or likely pathogenic variants, nor variants of uncertain significance (VUS). Variant-negative patients were older at diagnosis than variant-positive ones (38.2±13.6 vs. 28.4±14.8 years; p=0.02). Fever and arthritis occurred with a similar frequency between the groups. Compared with the variant-positive patients, the variant-negative group more often presented with nausea, weight loss, diarrhoea, erythema nodosum, headache, and sensorineural hearing loss (SNHL). Cerebrovascular occlusion occurred more frequently among variant-positive patients.Conclusion: Our study illustrates that the yield of genetic screening is expected to be low in patients older than 40 years and those presenting with nausea, weight loss, diarrhoea, erythema nodosum, headache, and SNHL. A better definition of those variant-negative patients may identify some subgroups of patients with SAID features associated with potential multifactorial causes or somatic mosaic variants.

  • Open Access

    Autoantibody origins in lupus and in relapse post CAR-T therapy

    by Amalie Grenov, Jongwon Yoon, Daniel M. Snell, Anna Mikolajczak, Hao Wang, Erdem Gürel, Ana Rodriguez Ronchel, Gülçin Yegen, Lydia Lee, Bahar Artim Esen, et al.

    Summary: Anti-CD19 chimeric antigen receptor (CAR)-T therapy induces profound remissions in lupus by depleting B cells, challenging the longstanding view that treatment-resistant disease is sustained by long-lived plasma cells. Additionally, emerging relapses highlight the need to understand how pathogenic autoantibodies arise. Using molecular antibody tagging in mice with human monogenic lupus variants, we reveal that autoantibody-producing cell cohorts are long-lived but plasma cells are short-lived, requiring continuous replenishment from proliferating precursors. The spleen acts as a major plasma cell reservoir, with perivascular localization conserved in mice and lupus patients. Relapse after anti-CD19 CAR-T occurred through newly-generated B cells rather than treatment-resistant clones. Plasma cell depletion by anti-BCMA CAR-T failed to eliminate some precursors that become autoantibody-secreting. These findings demonstrate that continuous B cell-to-plasma cell differentiation, not intrinsic plasma cell longevity, sustains pathogenic antibody responses in lupus, supporting a potential benefit of adjunctive therapies after CAR-T, particularly in genetically predisposed patients.


  • Open Access

    Discontinuation of hydroxychloroquine due to suspected retinal toxicity in systemic lupus erythematosus and the role of multimodal imaging

    by Burak İnCe, Mehmet Bedi̇i̇ Oğurel, Zafer Cebeci̇, Yavuz Burak Tor, Yasemi̇n Yalçinkaya, Ahmet Gül, Murat İnAnç, Bahar Artim Esen

    Background/aim: To evaluate the effect of hydroxychloroquine (HCQ) on disease activity and damage in patients with systemic lupus erythematosus (SLE) in whom HCQ had previously been discontinued due to retinal toxicity, and to examine and reevaluate toxicity findings through a detailed ophthalmological examination. Materials and methods: Patients with SLE who had been on HCQ for at least 3 years after achieving lupus low disease activity state (LLDAS) following remission induction, and were followed up for at least 3 years after HCQ discontinuation due to retinal toxicity diagnosed by visual field testing, were analysed. Disease activity, the number and severity of flares and damage were recorded whilst on HCQ and after cessation. All patients were examined by two ophthalmologists using multimodal imaging techniques to further analyse toxicity. Results: Sixty-one patients (age at diagnosis 33.4 ± 10.5, 88.5% female) were included. The percentage of visits maintaining LLDAS was significantly higher during HCQ treatment (p = 0.001). A significant number of patients experienced flares after HCQ discontinuation, with the mild–moderate type predominating (p = 0.006 and p = 0.026). Mean damage scores were higher at the end of the study period (p = 0.001). In the ophthalmologic examination (mean duration after drug cessation: 70.3 ± 52.3 months), signs of HCQ toxicity were not detected in 40 patients (65.6%), and HCQ was reinitiated for these patients. Of 21 (34.4%) patients who had visual field defects in reexamination, only five (8.2%) had typical retinal toxicity by multimodal imaging. Sixteen (26.2%) patients had macular atrophy due to other causes. Conclusion: Hydroxychloroquine is effective in controlling disease activity and preventing damage in SLE, and the opportunity for remedication is valuable. More than half of the patients who could restart HCQ after reexamination show the importance of performing multimodal imaging to diagnose retinal toxicity and to distinguish macular pathologies with different aetiological background.

  • Open Access

    Transient elastography measurements of the liver and transplanted kidney in patients with AA amyloidosis: a cross-sectional comparative study

    by Murat Bektaş, Bilger Çavuş, Besim Fazıl Ağargün, İbRahim Volkan Şenkal, Nevzat Koca, Burak İnCe, Selma Sarı, Ahmet Burak Dirim, Metban Güzel Mastanzade, Gizem Dağcı, et al.

    To evaluate the utility of elasticity imaging techniques, such as transient elastography (FibroScan), in assessing the liver and transplanted kidney in patients with AA amyloidosis (AA-A). This study was conducted in patients with AA-A, while patients with immunoglobulin light chain amyloidosis (AL-A), Familial Mediterranean Fever (FMF) without amyloidosis, and healthy controls (HC) were included as comparison groups for liver stiffness (LS) measurements. Additionally, kidney stiffness (KS) was measured in renal transplant recipients (RTRs) with transplants due to AA-A or other causes of chronic renal failure. LS evaluations were performed in 65 patients with AA-A, 14 with AL-A, 20 with FMF, and 27 with HC. LS (kPa) was significantly higher [median (IQR)] in patients with AA-A [6.4 (5.4)] and AL-A [9.8 (11)] compared to HC [4.7 (1.7)] (p < 0.001). However, the difference between AL-A and AA-A was not statistically significant. LS values were comparable in FMF-AA patients with [6.8 (6.6)] and without [5.7 (3.6)] liver involvement, and FMF patients without amyloidosis [7.15 (4.6)]. The median KS values were comparable in 19 AA-A and 16 disease controls. However, KS values were significantly higher in patients with recurrent amyloidosis in the transplanted kidney [29.3 (18.9)] compared to those without recurrence [10.9 (7.7)] (p = 0.003). In our study, increased liver stiffness measurements were observed in patients with AA-A, AL-A, and FMF compared to HC. Transient elastography using FibroScan appears to be a promising non-invasive tool for assessing liver involvement in AA-A and may aid in detecting recurrence of amyloidosis in transplanted kidneys. Further studies are needed to validate the utility of FibroScan in evaluating the involvement of the liver and kidneys in patients with AA-A.